The Conversation (0)
Stellar Biotechnologies Inc. (TSXV:KLH,OTCQB:SBOTF) announced that it exceeded its 2012 aquaculture capacity goal by almost 30 percent. The expansion is aimed at increasing capacity for future demand for keyhole limpet hemocyanin (KLH).
Stellar Biotechnologies Inc. (TSXV:KLH,OTCQB:SBOTF) announced that it exceeded its 2012 aquaculture capacity goal by almost 30 percent. The expansion is aimed at increasing capacity for future demand for keyhole limpet hemocyanin (KLH).
As quoted in the press release:
Following expansion of Stellar’s physical plant in 2011, the Company developed new and proprietary methods for cultivating limpets that ensures unprecedented survival rates of this important natural resource. Stellar’s hatchery innovations and controlled conditions have optimized the Company’s production; increasing yields and setting the stage for long-term KLH capacity while reducing environmental impact.
The net result, given sufficient funding, is to accelerate Stellar’s projected KLH production capacity to as much as 5 kilograms per year within the next four years, to 20 kilograms per year a few years later.
Frank Oakes, president and CEO of Stellar, commented:
This positions Stellar as the only company that will be capable of supplying GMP grade KLH that can meet the anticipated long-term demand within the pharmaceutical industry.This is a testament to our customer focus and operational excellence.
Click here to read the full Stellar Biotechnologies Inc. (TSXV:KLH,OTCQB:SBOTF) press release.Â
